编号：2021002 证券代码：002795 证券简称：永和智控 永和流体智控股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------------------|-----------|----------------------------------------------------|-----------------------------------------------| | | | | | | | | √特定对象调研 □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | | □其他 | | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | | 信达证券股份有限公司 工银瑞信基金管理有限公司 丁洋 | 周平 | | | | | | | 时间 2021年7 | 月7日 | | 15:00 | | 地点 | | 四川省成都市高新区天府三街88号 | 5栋23 层公司会 | | | 议室 | | | | | | | | ...

证券代码：002795 证券简称：永和智控 永和流体智控股份有限公司 投资者关系活动记录表 编号：2021001 | --- | --- | --- | |------------------------|-----------------------------------------------|----------------------------------------------------| | | | | | | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | | □新闻发布会 □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | | | 参与单位名称及人员姓名 | 中国银河证券 孟令伟 | | | 时间 2021 | 年6月 | 30日 15：30 | | | | | | 地点 | 昆明医科肿瘤医院会议室 | | | 上市公司接待人员姓名 | | 副总经理、董事会秘书 刘杰 | | | 构提问，公司回答的方式展开） 一、公司基本情况 | 调研公司发展和行业情况（以公司介绍基本情况 ...

Company Overview - Yonghe Fluid Control Co., Ltd. was founded in 2003 and listed on the Shenzhen Stock Exchange in April 2016 [1] - The company shifted its focus to the health care industry after a change in actual control in September 2019 [1] Business Model and Strategy - The company aims to expand in the niche of precision radiotherapy for tumors, establishing chain medical institutions across the country [2] - It relies on self-built and newly established models, supplemented by acquisitions, to create a network of specialized hospitals [2] - The company has already established four specialized tumor hospitals and plans to open 5-7 more in the Southwest region by 2022 [6] Market Potential - Approximately 70% of cancer patients require radiotherapy at various stages of their disease [3] - In 2015, only 23% of cancer patients in China received radiotherapy, significantly lower than the 60% in the United States [3] - As of 2019, China had only 2.7 radiotherapy devices per million people, compared to 14.4 in the U.S. [3] Competitive Advantages - The company has a leading edge in medical equipment, utilizing advanced radiotherapy devices such as Gamma Knife and linear accelerators [2] - It has built a team of experts with over 20 years of experience in precision radiotherapy [2] - The company has established a standardized operational system to facilitate rapid hospital setup and management [4] Industry Barriers - High entry barriers exist due to strict regulatory policies, significant capital investment, and the need for specialized talent [5] - New entrants face challenges in establishing brand reputation and clinical expertise in a complex medical field [5] Future Plans - The company plans to continue expanding its network of specialized hospitals, focusing on high-value cities [6] - It aims to enhance its operational efficiency and profitability through a combination of equipment and talent [6] - The funding for acquisitions primarily comes from the company's own resources, with a strong cash flow and good credit standing [7]

永和流体智控股份有限公司 2022 年第三季度报告 证券代码：002795 证券简称：永和智控 公告编号：2022-087 永和流体智控股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 永和流体智控股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 267,292,258.24 | -9.35% | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥530,474,100.21, representing a 24.94% increase compared to ¥424,568,719.79 in the same period last year[23]. - The net profit attributable to shareholders for the first half of 2022 was ¥31,499,025.19, up 23.44% from ¥25,517,293.28 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥33,620,193.29, a significant increase of 44.62% compared to ¥23,247,063.08 in the same period last year[23]. - The net cash flow from operating activities reached ¥99,705,749.37, marking a substantial increase of 610.75% from ¥14,028,211.58 in the previous year[23]. - The total assets at the end of the reporting period were ¥1,516,156,849.94, reflecting a 0.63% increase from ¥1,506,596,737.33 at the end of the previous year[23]. - The net assets attributable to shareholders increased by 7.81% to ¥830,710,439.47 from ¥770,553,263.72 at the end of the previous year[23]. - Basic earnings per share decreased by 15.38% to ¥0.11 from ¥0.13 in the same period last year[23]. - The diluted earnings per share also decreased by 15.38% to ¥0.11 from ¥0.13 in the previous year[23]. - The weighted average return on net assets was 3.89%, slightly up by 0.03 percentage points from 3.86% in the previous year[23]. - The company reported a total profit for the same period of 38.30 million yuan, reflecting a growth of 13.03% compared to the previous year[47]. Strategic Initiatives - The company is expanding into the precision radiotherapy sector, addressing the growing cancer incidence in China, which is projected to reach 5.1 million new cases by 2025[32]. - The company has established a strategic platform through its subsidiary Chengdu Yonghe Cheng Medical Technology Co., Ltd., focusing on precision radiotherapy services across major cities[35]. - The company plans to enhance its hospital network by integrating advanced medical imaging and radiotherapy equipment, including PET-CT and linear accelerators[37]. - The company has signed cooperation agreements with major hospitals to facilitate technology support, talent training, and data sharing in the oncology field[39][40]. - The company aims to fill the gap in radiotherapy resources in China, where only 20%-30% of cancer patients receive radiotherapy compared to 70% in developed countries[33]. - The company is committed to building a robust oncology treatment network, leveraging both self-built facilities and strategic acquisitions[37]. - The company is focusing on the core operational capabilities in the field of tumor precision radiotherapy, enhancing hospital management and service quality[48]. - The company is pursuing a dual strategy of "external mergers and acquisitions + internal growth" to expand quality medical resources and scale operations[52]. Operational Efficiency - The company is implementing a machine replacement plan to optimize production processes and improve efficiency through automation[48]. - The company has equipped its hospitals with advanced tumor precision radiotherapy and imaging diagnostic equipment to provide comprehensive medical services[53]. - The company has built a team of experienced medical professionals, ensuring a strong foundation for rapid growth in the tumor radiotherapy sector[55]. - The company has established stable partnerships with large multinational enterprises, enhancing its competitive advantage in the global market despite recent trade tensions affecting its U.S. market presence[57]. - The company has implemented an ERP system for integrated management, improving responsiveness to customer demands and ensuring timely product delivery[58]. Market and Sales - The revenue from the medical services and other industries saw a remarkable increase of 102.95%, reaching ¥71,280,115.49 compared to ¥35,121,601.08 last year[64]. - The average number of radiotherapy devices per million people in first-tier cities is 4.9, significantly lower than the 14.4 in the United States, indicating a market opportunity[34]. - The company is expanding its market resources through intermediary channels to stabilize sales and increase customer orders amid the ongoing impact of the COVID-19 pandemic[49]. - Approximately 50% of the company's sales are generated from the US market, indicating a high dependency on international trade, which poses risks amid potential trade tensions[85]. Financial Management - The company has strengthened inventory management, leading to faster inventory turnover and reduced stock levels[70]. - The company has increased its prepayments to secure material procurement prices, indicating a proactive approach to cost management[70]. - The company emphasizes risk management in foreign exchange forward contracts to mitigate currency fluctuation risks[78]. - The company has implemented strict internal controls to manage risks associated with foreign exchange transactions[78]. - The company is focused on maintaining stable profit levels despite potential currency volatility[78]. - The company has established a mechanism to adjust pricing based on exchange rate fluctuations to manage currency risk effectively[89]. Shareholder and Capital Structure - The company plans not to distribute cash dividends or issue bonus shares[5]. - The 2019 stock option incentive plan allows 19 eligible participants to exercise 7.378 million options at a price of ¥14.19 per share, representing 3.53% of the total share capital[97]. - The exercise price for the 2019 stock option plan was adjusted from ¥14.19 to ¥10.14, with the number of unexercised options increasing from 9.2225 million to 12.9115 million[98]. - The 2022 restricted stock incentive plan involves granting 11.5 million shares at a price of ¥5.57 per share to 60 participants[100]. - The company reported a cumulative increase of 10,928,376 shares, accounting for 3.54% of the total share capital, with an investment amount of approximately RMB 89.75 million[112]. - The total number of ordinary shareholders at the end of the reporting period was 16,770, with significant shareholders including Cao Deli holding 16.25% (47.6 million shares) and Chen Xianyun holding 7.98% (23.37 million shares)[147]. Compliance and Governance - The financial statements were prepared in accordance with the accounting standards issued by the Ministry of Finance and relevant regulations[196]. - The financial report was approved by the board of directors on August 26, 2022[195]. - The company has not reported any significant changes in accounting policies compared to the previous reporting period[78]. - The company has not engaged in any major asset or equity sales during the reporting period[80][81]. - There were no fundraising activities reported during the period[79]. - The company has not reported any significant litigation or arbitration matters during the reporting period[116]. - The company did not engage in any major related party transactions during the reporting period[117].

Financial Performance - The company's operating revenue for 2021 was ¥1,008,508,895.38, representing a 55.71% increase compared to ¥647,691,188.74 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥18,682,917.51, a 44.55% increase from ¥12,924,662.58 in 2020[18]. - The net profit after deducting non-recurring gains and losses for 2021 was ¥14,705,244.35, showing a 73.22% increase from ¥8,489,349.07 in 2020[18]. - The net cash flow from operating activities for 2021 was ¥115,162,707.14, which is a 103.93% increase compared to ¥56,472,415.67 in 2020[18]. - The total assets at the end of 2021 were ¥1,506,596,737.33, reflecting a 27.04% increase from ¥1,185,934,827.59 at the end of 2020[18]. - The net assets attributable to shareholders at the end of 2021 were ¥770,553,263.72, a 20.56% increase from ¥639,140,711.44 at the end of 2020[18]. - The company achieved total revenue of 1,008.51 million yuan in 2021, representing a year-on-year growth of 55.71%[45]. - The net profit attributable to the parent company was 186.83 million yuan, an increase of 44.55% compared to the previous year[45]. - The total operating revenue for the year 2021 reached ¥1,008,508,895.38, representing a year-on-year increase of 55.71% compared to ¥647,691,188.74 in 2020[63]. - The industrial segment contributed ¥918,323,094.84, accounting for 91.06% of total revenue, with a year-on-year growth of 52.39%[63]. - The medical services and other industries saw a revenue increase of 100.10%, reaching ¥90,185,800.54, up from ¥45,070,534.16 in 2020[63]. Business Strategy and Expansion - The company plans to expand into the precision radiation therapy sector, driven by the increasing cancer incidence in the aging population[27]. - The projected number of new cancer cases in China is expected to reach 499 million by 2024 and 570 million by 2030, indicating a growing market opportunity[28]. - The company focuses on building a chain of specialized cancer hospitals in key cities, integrating advanced medical imaging and radiation therapy technologies[36]. - The company aims to address the imbalance in radiation therapy resources between first-tier and lower-tier cities, where demand significantly exceeds supply[30]. - The company is strategically expanding its presence in high-value cities and emerging markets to build a nationwide cancer treatment service network[52]. - The company is developing a lead-free threaded ball valve to meet European market standards, currently in mass production phase[76]. - The company aims to establish a chain of specialized hospitals focused on precision radiation therapy for tumors, targeting high-value cities and emerging markets[106]. - The company plans to enhance its product supply capabilities by developing integrated solutions in the water system and HVAC sectors[107]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with a budget of RMB 300 million allocated for potential deals[152]. Operational Efficiency and Management - The company is implementing a "dual control" energy consumption policy, adjusting production schedules to minimize the impact of power restrictions[47]. - The company is promoting a "machine replacement" plan to optimize production processes and reduce labor costs through automation[48]. - The company emphasizes talent development, focusing on internal talent cultivation and management to support business growth[50]. - The company has established partnerships with major hospitals to enhance service capabilities and improve patient care through collaborative agreements[39]. - The company has implemented an ERP system for integrated management, improving responsiveness to customer demands[59]. - The company has a structured training program aimed at enhancing employee capabilities and aligning with strategic goals[170]. - The company has a differentiated compensation structure based on employee levels and categories, ensuring internal equity and external competitiveness[169]. - The company is focused on maintaining advanced technology through continuous upgrades and expansions in its valve and fitting business[178]. Financial Management and Investments - The company reported a cash dividend of 0.00 RMB per 10 shares and a capital reserve increase of 4 shares for every 10 shares held[6]. - The company has a cash dividend policy in place but did not propose any cash dividends for 2021, opting instead for a capital reserve increase of 4 shares for every 10 shares held[173]. - The company reported a total of ¥58.23 million in investment properties, which are also subject to mortgage guarantees[89]. - The company has pledged 100% equity of its subsidiaries for bank loans, with total restricted assets valued at approximately ¥290.71 million[91]. - The company reported a significant focus on the development of the medical health industry, particularly in the field of precision radiation therapy for tumors[122]. - The company plans to continue its forward foreign exchange settlement business to manage financial risks effectively[162]. - The company has engaged in a significant asset restructuring plan involving the sale of 100% equity in Zhejiang Yonghe Zhikong Technology Co., Ltd. to Zhiba Technology (Zhejiang) Co., Ltd.[163]. Governance and Compliance - The company held one annual general meeting and four extraordinary general meetings during the reporting period, ensuring compliance with legal requirements for shareholder participation[123]. - The company maintains independence from its controlling shareholder, with no instances of non-operational fund occupation reported[124]. - The board of directors operates in accordance with legal and regulatory requirements, ensuring effective governance and oversight[125]. - The company has established a transparent performance evaluation and incentive mechanism for its directors, supervisors, and senior management, enhancing operational efficiency[128]. - The company's internal audit reports for 2021 confirmed compliance with financial reporting standards and highlighted the integrity of its financial practices[162]. - The company has established a comprehensive internal control system that has been effectively implemented, with no significant defects reported during the reporting period[189]. Market Challenges and Risks - The company faces risks related to industry policy changes that may impact private capital investment in medical services, particularly in tumor precision radiotherapy[112]. - The company has a significant portion of its hospital revenue tied to local medical insurance, which may face pressure as the business scales[113]. - The company is at risk of goodwill impairment due to acquisitions in the healthcare sector, necessitating a focus on improving hospital operational and profitability capabilities[114]. - The valve and fittings business is exposed to foreign exchange risks, particularly with the US dollar, and will implement hedging strategies to mitigate these risks[115]. - The company will track raw material price trends, particularly copper, which constitutes approximately 60% of production costs, to manage price volatility effectively[116].

永和流体智控股份有限公司 2022 年第一季度报告全文 证券代码：002795 证券简称：永和智控 公告编号：2022-029 永和流体智控股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性 陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、 准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 250,022,104.21 | 180,406,859.36 | 38.59% | | 归属于上市公司股东的净利润（元） | 12,478,199.47 | 7,390,662.30 | 68.84% | | 归属于上市公司股东的扣除非经常性损 ...

Financial Performance - The company's revenue for Q3 2021 reached ¥294,847,063.85, representing an increase of 86.43% compared to the same period last year[3] - Net profit attributable to shareholders was ¥1,549,625.93, a decrease of 75.37% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥1,232,219.65, down 79.45% from the previous year[3] - Total operating revenue for the third quarter reached ¥719,415,783.64, a significant increase from the previous period's revenue of ¥462,392,212.54[21] - The net profit for Q3 2021 was CNY 27,284,046.62, a decrease of 24.1% compared to CNY 35,975,928.62 in Q3 2020[23] - Operating profit for Q3 2021 was CNY 42,287,355.99, down from CNY 48,626,612.87 in the same period last year, reflecting a decline of 13.7%[23] - The company experienced a total profit of CNY 42,225,666.83 in Q3 2021, which is a decrease of 12.5% from CNY 48,273,639.49 in Q3 2020[23] - The total comprehensive income attributable to the parent company for Q3 2021 was CNY 27,069,491.56, compared to CNY 35,938,457.39 in Q3 2020, a decrease of 24.4%[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,336,829,712.11, an increase of 12.72% compared to the end of the previous year[4] - Current liabilities totaled ¥489,816,133.43, an increase from ¥458,449,238.26, indicating a rise in short-term financial obligations[19] - The total equity attributable to shareholders rose to ¥714,719,370.08 from ¥639,140,711.44, demonstrating improved shareholder value[20] - Total assets amounted to CNY 1,185,934,827.59, a decrease of CNY 78,879,544.18 compared to the previous period[32] - Non-current liabilities increased to CNY 86,510,976.20, reflecting an increase of CNY 78,876,488.24 compared to the previous period[31] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥29,338,580.55, a decline of 56.46% compared to the same period last year[11] - Cash flow from operating activities for Q3 2021 was CNY 29,338,580.55, significantly lower than CNY 67,386,538.08 in Q3 2020, representing a decrease of 56.4%[26] - The company reported a net cash outflow from investing activities of CNY -20,230,488.44 in Q3 2021, compared to CNY -151,931,842.79 in Q3 2020[27] - The company’s total cash inflow from financing activities in Q3 2021 was CNY 444,566,892.67, compared to CNY 488,600,000.00 in Q3 2020, reflecting a decrease of 9.0%[27] - The cash and cash equivalents at the end of Q3 2021 were CNY 105,806,832.41, down from CNY 181,896,302.50 at the end of Q3 2020, a decline of 41.8%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,778[12] - The largest shareholder, Cao Deli, holds 16.75% of the shares, amounting to 34,000,000 shares, with 25,500,000 shares pledged[12] - The second largest shareholder, Chen Xianyun, holds 8.22% of the shares, totaling 16,692,400 shares[12] - The third largest shareholder, Yang Yingli, holds 6.89% of the shares, amounting to 13,980,000 shares[12] - The company has not disclosed any other significant shareholder relationships beyond those mentioned[12] Research and Development - Research and development expenses increased by 69.48% to ¥16,878,871.98, reflecting higher investment in R&D materials[9] - Research and development expenses were reported at ¥16,878,871.98, up from ¥9,959,089.40, reflecting the company's commitment to innovation[21] Strategic Initiatives - The company is in the process of selling 100% equity of Zhejiang Yonghe Zhikong Technology Co., Ltd. to Zhiba Technology, which includes all rights to its subsidiaries[14] - The company is actively conducting audits and evaluations related to the asset sale, with board meetings planned to review the transaction[14] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[21] Stock Options - The stock option incentive plan has allowed 21 eligible participants to exercise 3.02 million options at a price of 14.19 RMB per share[15] - The company has a total of 934,750 stock options available for exercise under the incentive plan[15]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥424.57 million, representing a 39.55% increase compared to ¥304.24 million in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 13.81% to approximately ¥25.52 million, down from ¥29.60 million in the previous year[19]. - The net cash flow from operating activities fell by 49.62% to approximately ¥14.03 million, compared to ¥27.84 million in the same period last year[19]. - Total assets at the end of the reporting period increased by 12.42% to approximately ¥1.33 billion, up from ¥1.19 billion at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased by 5.44% to approximately ¥673.94 million, compared to ¥639.14 million at the end of the previous year[19]. - The basic earnings per share decreased by 13.33% to ¥0.13, down from ¥0.15 in the same period last year[19]. - The weighted average return on net assets decreased by 0.89 percentage points to 3.86% compared to 4.75% in the previous year[19]. - The total profit for the same period was 33.89 million CNY, which is a decrease of 13.30% compared to the previous year[36]. - The company's total revenue reached ¥424,568,719.79, representing a year-on-year increase of 33.47%[57]. - The gross profit margin for the industrial sector decreased by 3.73 percentage points to 28.60%[57]. - The total profit for the first half of 2021 was CNY 33,886,786.14, a slight decrease from CNY 39,086,510.64 in the same period of 2020[172]. Healthcare Sector Focus - The company is strategically entering the healthcare industry, focusing on precision radiation therapy for tumors, and plans to divest its fluid control business[27]. - The demand for cancer treatment in China is increasing, with new cancer cases expected to rise from approximately 4.4 million in 2019 to about 5.11 million by 2025[28]. - The company has established a platform for medical industry development through its wholly-owned subsidiary, Chengdu Yonghe Medical Technology Co., Ltd., focusing on tumor treatment services[30]. - The company has acquired Dazhou Medical Oncology Hospital and Kunming Medical Oncology Hospital, and has established a new hospital in Chongqing, expanding its network of specialized cancer treatment facilities[33]. - The company aims to enhance its operational capabilities in the healthcare sector by implementing refined management practices and establishing a comprehensive operational management system for its chain hospitals[38]. - The company is integrating advanced medical imaging and radiation therapy equipment in its hospitals to provide precise treatment for cancer patients[31]. - The radiation therapy adoption rate in China is significantly lower than in developed countries, indicating substantial growth potential in the market[29]. - The company has established a clear service positioning in the healthcare sector, targeting the growing demand for tumor precision radiotherapy amid an aging population and rising cancer incidence[42]. - The company has invested in multiple medical facilities, including Dazhou Medical Oncology Hospital and Kunming Medical Oncology Hospital, to strengthen its presence in the healthcare market[54]. Operational Risks and Management - The company faces various operational risks and has outlined corresponding countermeasures in its report[5]. - The company is actively restructuring its asset portfolio by divesting its traditional valve and pipe fittings business to focus on the healthcare sector, which is expected to enhance its capital for medical industry expansion[40]. - The company is addressing the risk of delayed medical insurance reimbursements by enhancing its brand reputation and reducing reliance on insurance payments[81]. - There is a risk of goodwill impairment due to acquisitions of hospitals, prompting the company to focus on improving operational and profitability metrics[82]. - The company is exposed to foreign exchange risks due to its reliance on exports, particularly in USD, and is implementing pricing mechanisms to mitigate this risk[83]. Investment and Financial Strategy - Research and development investment rose by 60.09% to approximately ¥9.53 million, compared to ¥5.96 million in the previous year, indicating a focus on enhancing R&D capabilities[52]. - The company plans to focus on the healthcare industry after exiting the fluid control business, which will optimize its capital structure and reduce financial costs[77]. - The company aims to enhance its sustainable development capabilities by investing the recovered funds into the healthcare industry[77]. - The company has implemented measures to avoid overdue accounts receivable and reduce customer default risks by purchasing credit insurance[74]. - The company has committed to a share buyback plan, with a target of acquiring between 1.9072 million and 2 million shares[112]. - The company applied for a total credit limit of up to RMB 600 million from banks to support development plans and strategic implementation[133]. Shareholder and Equity Information - The company did not distribute cash dividends or issue new shares in the first half of the year, maintaining its capital structure[88]. - The company has completed all commitments made by actual controllers, shareholders, and related parties during the reporting period[102]. - The company has fulfilled its commitment regarding the reduction of shareholding, allowing a maximum reduction of 5% of total shares within 24 months after the lock-up period[102]. - The company has ensured that any future compensation measures will be linked to the execution of relevant commitments[103]. - The company has not made any unfair conditions for other units or individuals that would harm the company's interests[103]. - The company has a total of 47,980,000 shares held by directors and supervisors at the beginning and end of the reporting period[151]. - The total number of common shareholders at the end of the reporting period was 15,251[148]. - The largest shareholder, Cao Deli, holds 17.00% of the shares, amounting to 34,000,000 shares, with 25,500,000 shares pledged[148]. - The company reported no changes in the number of shares held by directors and senior management during the reporting period[151]. Future Outlook and Strategic Initiatives - The company plans to continue focusing on market expansion and new product development to drive future growth[170]. - The company anticipates a gradual recovery in performance in the upcoming quarters, supported by strategic initiatives and market expansion efforts[190]. - The company aims to expand its market presence and enhance product development in the upcoming periods[197]. - The company is focusing on technological innovation and the development of new products to drive future growth[197]. - The company has plans for strategic investments and potential mergers to strengthen its market position[197].

永和流体智控股份有限公司 2021 年第一季度报告全文 永和流体智控股份有限公司 2021 年第一季度报告 2021 年 04 月 1 永和流体智控股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减 | | 营业收入（元） | 180,406,859.36 | 130,945,135.99 | 37.77% | | 归属于上市公司股东的净利润（元） | 7,390,662.30 | 7,777,412.59 | -4.97% | | 归属于上市公司股东的扣除非经常性 损益的净利润（元） | 6,903,617.33 | 7,193,090.53 | -4.02% | | 经营活动产生的现金流量净额（元） | 17,538,692.11 | 15,137,90 ...